Skip to main content

Table 2 COVID-19 patients

From: Nonthyroidal illness syndrome (NTIS) in severe COVID-19 patients: role of T3 on the Na/K pump gene expression and on hydroelectrolytic equilibrium

  Normal FT3 (n. 32)
Mean (St. Dev.)
Low FT3 (n. 29)
Mean (St. Dev.)
Very low FT3 (n. 13)
Mean (St. Dev.)
Total (n. 74)
Mean (St. Dev.)
Sex (F/M) 17/15 14/15 7/6 38/36
Age (years), mean (st. dev.) 63.5 (± 13.8) 65.4 (± 13.7) 65.1 (± 10.1) 64.5 (± 13.1)
BMI, mean (st. dev.) 29.5 (± 7.5) 27.1 (± 4.2) 31.4 (± 7.6) 28.9 (± 6.6)
FT3 (pg/ml), mean (st. dev.) 2.2 (± 0.4) 1.5 (± 0.1) 1.0 (± 0.0) 1.7 (± 0.6)
FT4 (ng/dl), mean (st. dev.) 1.0 (± 0.2) 1.0 (± 0.2) 0.9 (± 0.2) 1.0 (± 0.2)
TSH (μIU/ml), mean (st. dev.) 1.4 (± 1.3) 0.8 (± 0.9) 0.6 (± 0.8) 1.0 (± 1.1)
Comorbidity (at least one) n. (%) 26 (81.3) 24 (82.7) 13 (100) 63 (85.1)
Hypertension, n. (%) 23 (71.9) 17 (58.6) 11 (84.6) 51 (68.9)
Diabetes, n. (%) 15 (46.9) 8 (27.6) 6 (46.2) 29 (39.2)
Obesity, n. (%) 9 (28.1) 4 (13.8) 5 (38.5) 18 (24.3)
Malignancy, n. (%) 2 (6.3) 6 (20.7) 8 (19) 16 (21.6)
Ischemic heart disease, n. (%) 8 (25.0) 5 (17.2) 1 (7.7) 14 (18.9)
Arrhythmogenic cardiac diseases, n. (%) 1 (3.1) 2 (6.9) 1 (7.7) 4 (5.4)
Autoimmune disease, n. (%) 2 (6.3) 2 (6.9) 0 (0) 4 (5.4)
Chronic obstructive pulmonary disease, n. (%) 2 (6.3) 1 (3.4) 0 (0) 3 (4.0)
Psychiatric disease, n. (%) 1 (3.1) 1 (3.4) 1 (7.7) 3 (4.0)